2.84
price down icon9.27%   -0.29
after-market Handel nachbörslich: 2.84
loading
Schlusskurs vom Vortag:
$3.13
Offen:
$3.02
24-Stunden-Volumen:
190.85K
Relative Volume:
1.30
Marktkapitalisierung:
$84.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.08M
KGV:
-6.4312
EPS:
-0.4416
Netto-Cashflow:
-
1W Leistung:
-29.35%
1M Leistung:
-30.90%
6M Leistung:
-49.10%
1J Leistung:
-48.87%
1-Tages-Spanne:
Value
$2.83
$3.10
1-Wochen-Bereich:
Value
$2.73
$4.0607
52-Wochen-Spanne:
Value
$2.73
$9.39

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name
Firmenname
Telomir Pharmaceuticals Inc
Name
Telefon
786-396-6723
Name
Adresse
100 SE 2ND ST, MIAMI
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
TELO's Discussions on Twitter

Vergleichen Sie TELO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TELO
Telomir Pharmaceuticals Inc
2.84 84.53M 0 -13.08M 0 -0.4416
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-21 Eingeleitet Rodman & Renshaw Buy

Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten

pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Apr 01, 2025
pulisher
Mar 29, 2025

Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Mar 29, 2025
pulisher
Mar 25, 2025

Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World

Mar 25, 2025
pulisher
Mar 23, 2025

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 21, 2025

Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN

Mar 21, 2025
pulisher
Mar 19, 2025

SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir-1 shows promise in cancer and chemotherapy study - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan

Mar 19, 2025
pulisher
Mar 19, 2025

Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga

Mar 19, 2025
pulisher
Mar 12, 2025

Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World

Mar 12, 2025
pulisher
Mar 04, 2025

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World

Mar 04, 2025
pulisher
Feb 26, 2025

Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Telomir-1 shows promise in reversing cell aging - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune

Feb 26, 2025
pulisher
Feb 26, 2025

Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals reports key preclinical success - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN

Feb 25, 2025
pulisher
Feb 24, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World

Feb 24, 2025
pulisher
Feb 23, 2025

Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times

Feb 23, 2025
pulisher
Feb 21, 2025

Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir reports stabilization of silver forms for medical use - Investing.com

Feb 21, 2025
pulisher
Feb 21, 2025

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat

Feb 21, 2025
pulisher
Feb 20, 2025

Telomir Pharmaceuticals announces silver ion breakthrough - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - Benzinga

Feb 20, 2025
pulisher
Feb 18, 2025

TELO Again Announces Breakthrough Results - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) - Milton Daily Standard

Feb 18, 2025
pulisher
Feb 10, 2025

What is Zacks Small Cap's Estimate for TELO Q1 Earnings? - MarketBeat

Feb 10, 2025
pulisher
Feb 08, 2025

Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

What is Zacks Small Cap’s Estimate for TELO Q1 Earnings? - Defense World

Feb 08, 2025
pulisher
Feb 04, 2025

Telomir Pharmaceuticals Inc. (TELO) reports earnings - Quartz

Feb 04, 2025
pulisher
Feb 03, 2025

TELO Treatment Amazes in Preclinical Trial - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart

Feb 03, 2025
pulisher
Feb 02, 2025

Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart

Feb 02, 2025
pulisher
Jan 31, 2025

Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart

Jan 31, 2025

Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):